ZX 0851

Drug Profile

ZX 0851

Latest Information Update: 07 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Oklahoma Medical Research Foundation
  • Class Antivirals
  • Mechanism of Action RNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 07 Mar 2008 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
  • 30 Jul 1999 ZymeTx has returned licensing rights for ZX 0851 to Oklahoma Medical Research Foundation
  • 22 May 1998 Preclinical development for HIV infections treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top